Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/114492
Title: | Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study | Authors: | Sousa-Pinto, B Louis, R Anto, J M Amaral, R Sá-Sousa, A Czarlewski, W Brussino, L Canonica, G W Chaves Loureiro, C Cruz, A A Gemicioglu, B Haahtela, T Kupczyk, M Kvedariene, V Larenas-Linnemann, D E Okamoto, Y Ollert, M Pfaar, O Pham-Thi, N Puggioni, F Regateiro, F. S. Romantowski, J Sastre, J Scichilone, N Taborda-Barata, L Ventura, M T Agache, I Bedbrook, A Becker, S Bergmann, K C Bosnic-Anticevich, S Bonini, M Boulet, L-P Brusselle, G Buhl, R Cecchi, L Charpin, D de Blay, F Del Giacco, S Ivancevich, J C Jutel, M Klimek, L Kraxner, H Kuna, P Laune, D Makela, M Morais-Almeida, M Nadif, R Niedoszytko, M Papadopoulos, N G Papi, A Patella, V Pétré, B Rivero Yeverino, D Cordeiro, Carlos Robalo Roche, N Rouadi, P W Samolinski, B Savouré, M Shamji, M H Sheikh, A Suppli Ulrik, C Usmani, O S Valiulis, A Yorgancioglu, A Fonseca, J A Costa, E M Bousquet, J |
Keywords: | Asthma; Adherence; Inhaledcorticosteroids; Formoterol; Long-acting-b2agonist | Issue Date: | 3-Aug-2023 | Publisher: | Elsevier | Serial title, monograph or event: | Pulmonology | Abstract: | Introduction: Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA. Materials and methods: We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day. Results: In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001). Conclusions: In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control. | URI: | https://hdl.handle.net/10316/114492 | ISSN: | 25310437 | DOI: | 10.1016/j.pulmoe.2023.07.004 | Rights: | openAccess |
Appears in Collections: | I&D CIBB - Artigos em Revistas Internacionais FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma A MASK-air study.pdf | 642.64 kB | Adobe PDF | View/Open |
Page view(s)
92
checked on Oct 9, 2024
Download(s)
54
checked on Oct 9, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License